Blend · Vial
Verified record10mg
A two-peptide blend used to explore how different signals influence the body’s growth-hormone system.
Current batchCJCIPA 002-028
Published result99.1% reported purity
EternaGen / GLOW 003-017Blend · Research use only
Glow Blend
$200CAD
A three-peptide blend for laboratory research into tissue repair, skin biology and connective-tissue signalling.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Glow Blend, clearly explained.
A three-peptide blend for laboratory research into tissue repair, skin biology and connective-tissue signalling.
Overview
Glow contains BPC 157, GHK-Cu and TB-500. Each ingredient comes with a different kind and quality of research, and the complete blend has not been tested in controlled human studies.
The label identifies a 70 mg fixed blend containing BPC 157 10 mg, GHK-Cu 50 mg and TB-500 10 mg. Each component has a different evidence base, molecular identity and set of interpretation limits.- Format
- Pen
- Available strengths
- 70mg
- Batch
- GLOW 003-017
- Purity
- Verified
Research at a glanceComponent-level evidence only; fixed-blend clinical evidence not established
Reviewed 23 July 2026View research context Declared blend composition
- BPC 157 — 10 mg
- GHK-Cu — 50 mg
- TB-500 — 10 mg
The blend has not been studied as a whole. Research on one ingredient cannot predict how the complete mixture will behave.
Specifications
Product details
- Sequence / identity
- Confirm in batch record
- Molecular formula
- Confirm in batch record
- Molecular weight
- Confirm in batch record
- Storage and handling
- Follow the handling and storage conditions attached to the verified batch record.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- GLOW 003-017
- Purity
- Verified
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
BPC 157 component
Research interest centres on injury and connective-tissue models, with a major gap in controlled human evidence.
Evidence so far: Predominantly preclinicalQuestion 02
GHK-Cu component
Research includes fibroblast and topical wound models; route and formulation are essential context.
Evidence so far: Mechanistic plus narrow topical evidenceQuestion 03
TB-500 component
TB-500 fragment evidence must not be conflated with studies of full-length thymosin beta 4.
Evidence so far: Identity and translation gapProposed mechanism
How researchers are investigating the mechanism.
The blend combines compounds studied in different preclinical systems. No single mechanism can accurately summarize the mixture, and the effects of combining the components cannot be inferred by adding together findings from separate studies.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Component-level literature review
- What researchers saw
- The three named ingredients appear in distinct cell, animal or formulation-specific research programmes.
- Why that is not the whole story
- No controlled clinical study was identified for this 10:50:10 fixed combination.
Study 02Regulatory review of the named injectable peptides
- What researchers saw
- Regulators identify limited human safety information and route-specific impurity or immunogenicity concerns.
- Why that is not the whole story
- A batch purity result does not establish that the mixture is safe or effective for personal use.
Evidence gaps
What remains unknown?
- Interactions, stability and analytical recovery for the fixed mixture require blend-specific validation.
- No human efficacy or safety conclusions can be assembled by combining unrelated component studies.
- The exact batch composition and testing methods should be confirmed against the linked certificate.
Primary sources
Check the original sources.
- Component evidence mapPrimary studies for BPC 157, GHK-Cu and thymosin beta 4 are indexed in EternaGen Evidence by Compound.
- Canadian public advisoryHealth Canada. Advisory on unauthorized injectable peptides, including BPC-157, GHK-Cu and TB-500. 2026.
- Analytical standardICH Q2(R2). Validation of Analytical Procedures, including specificity for multi-analyte methods.
Related products
Continue comparing.
Blend · Vial
Verified recordKlow Blend
$22080mg
A four-peptide blend for laboratory research spanning tissue, skin and inflammatory-signalling models.
Current batchKLOW 002-009
Published resultVerified